According to Lundholm et al., research on prostate tumour‐derived TDE that expresses the NKG2D ligand preferentially downregulates NKG2D on NK and CD8+ T cells, impairing cytotoxic activity in vitro.39 Here, KLRK1 is linked to prostate neoplasm.